B+
Bull case
30%
Probability
Target price
$4.15
Analysis reference price unavailable
Analysis 2026-09-11 · RankAlpha Sentiment Codex
APYX
Apyx MedicalANasdaq / Health Care Equipment & Services
Last Price
Quote time unavailable
Current thesis
Revenue growth accelerated to 22%, Surgical Aesthetics grew 28%, and AYON adoption plus the PowerLipo capability could reinforce device placements and recurring handpiece demand. The deterministic prior remains positive, with a 12.73% expected 120-day return, although this is a model estimate rather than company guidance.
Posture
Constructive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite.
What can break
AYON and PowerLipo adoption evidence is still early; positive surgeon feedback does not establish broad placement, utilization, or recurring-revenue durability.
Momentum
87
Value
37
Sentiment
100
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $3.25 · Bull $4.15 · Bear $2.10Analysis 2026-09-11; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-17 • Vendor: Data Vendor v1
Scores
As of 2026-09-10 • Model: HYBRID_IC_RP
AI Memo
As of 2026-09-11 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-09-10
Investment thesis
As of 2026-09-10
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-10. Definitions
Supporting evidence
What
Grade A · Constructive
Confidence Medium · Net Neutral
Target $6.60
Why
Momentum87 · Δ7d -
Value37 · Δ7d -0.0
Sentiment100 · Δ7d -
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Confirming evidence
- • Sentiment remains the lead driver in the composite.
Contradictions & invalidation
- • AYON and PowerLipo adoption evidence is still early; positive surgeon feedback does not establish broad placement, utilization, or recurring-revenue durability.
- • Apyx reported an adjusted EBITDA loss in Q2, so revenue growth must translate into better operating leverage and cash generation.
- • APYX remains a small, low-coverage medtech issuer whose product momentum must translate into durable utilization, improving losses, and adequate liquidity.
Catalyst clock
2026-08-06
Q2 growth and FY2026 outlook reset
Lead driver: Sentiment · See AI snapshot
Momentum
87
9% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
37
28% active weight
Current posture
7d trendFlat
Δ7d
-0.0
Δ21d
+0.2
Sentiment
100
62% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade
Composite grade A. Momentum 87.1 / Value 36.6 / Sentiment 100.0
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-09-11. Scenario method
Most likely
B
Base case
50%
Probability
Target price
$3.25
Analysis reference price unavailable
Analysis 2026-09-11 · RankAlpha Sentiment Codex
B-
Bear case
20%
Probability
Target price
$2.10
Analysis reference price unavailable
Analysis 2026-09-11 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-08-17
Fundamentals (TTM)
As of 2026-08-17
Market Cap
$128.9M
Beta
1.59
Shares Out
42.12M
P/E (TTM) · Derived
-11.2
P/S (TTM)
3.03
P/FCF (TTM) · Derived
-11.70
Rev YoY
+22.1%
EPS YoY
-20.3%
Gross Margin
+38.7%
Op Margin
-6.1%
Net Debt
$7.6M
Current Ratio
5.68
As of 2026-09-10 • Updated nightlySource: Internal modelMethods & Data